| HSV vaccine (GEN-003) / Genocea, Shionogi |
NCT02114060: Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine |
|
|
| Completed | 2 | 310 | US | GEN-003 Vaccine (30μg of each antigen), HSV Vaccine, GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg), MM2, Adjuvant, Matrix-M2 Adjuvant (50μg), Matrix-M2 Adjuvant (75μg), Placebo, 0.9% Normal Saline (NaCl) | Genocea Biosciences, Inc. | Genital Herpes Simplex Type 2 | 02/16 | 02/16 | | |
NCT02300142: Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study |
|
|
| Completed | 2 | 37 | US | GEN-003 Vaccine (30μg of each antigen), HSV Vaccine, GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg), MM2, Adjuvant, Matrix-M2 Adjuvant (50μg), Matrix-M2 Adjuvant (75μg) | Genocea Biosciences, Inc. | Genital Herpes Simplex Type 2 | 06/16 | 06/16 | | |
NCT02515175: Evaluating New Formulation of Therapeutic HSV-2 Vaccine |
|
|
| Completed | 2 | 131 | US | Matrix-M2, Adjuvant, GEN-003, HSV Therapeutic Vaccine, Placebo, 0.9% Normal Saline | Genocea Biosciences, Inc. | Genital Herpes Simplex Type 2 | 07/16 | 05/17 | | |
NCT03146403: Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection |
|
|
| Terminated | 2 | 33 | US | GEN-003, HSV Therapeutic Vaccine, Matrix-M2, Adjuvant, 0.9% normal saline | Genocea Biosciences, Inc. | Genital Herpes, HSV-2 Infection | 12/17 | 06/18 | | |
NCT03270956: A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease |
|
|
| Completed | 2 | 10 | US | Renal Autologous Cell Therapy (REACT) | Prokidney, CTI Clinical Trial and Consulting Services | Type 2 Diabetes Mellitus, Chronic Kidney Disease | 11/22 | 11/22 | | |
NCT01667341: Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine |
|
|
| Completed | 1/2 | 143 | US | GEN-003 with Matrix M-2, GEN-003, Placebo, PBS, DPBS | Genocea Biosciences, Inc. | Genital Herpes Simplex Type 2 | 05/14 | 05/14 | | |
